Contract Manufacturing Services Wuxi Biologics Expands Manufacturing Capacity in USA

Source: Press release Wuxi Biologics 1 min Reading Time

Related Vendors

With the increasing demand for contract manufacturing services from global clients, Wuxi Biologics has plans to expand its production capacity at its Worcester facility in Massachusetts, USA. With this move, the unit will add 12,000 liters of commercial drug substance capacity to its existing capacity of 24,000 liters.

Wuxi Bio has recently announced that it will increase the total manufacturing capacity of its facility in Worcester, Massachusetts to 36,000 liters.(Source:  Pixabay)
Wuxi Bio has recently announced that it will increase the total manufacturing capacity of its facility in Worcester, Massachusetts to 36,000 liters.
(Source: Pixabay)

Worcester/USA – Wuxi Biologics (Wuxi Bio), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has recently announced that it will increase the total manufacturing capacity of its facility in Worcester, Massachusetts to 36,000 liters.

In response to global clients’ increasing demand for contract manufacturing services, the Worcester facility, known as MFG11, will add 12,000 liters of commercial drug substance capacity, up from a planned 24,000 liters. Construction of the 189,500-square-foot facility is underway and recently achieved weather tight status. The facility anticipates being operational in 2025 with GMP release in 2026.

Wuxi Biologics currently employs over 400 people in the U.S., and the Worcester facility will create an additional 200 new jobs when fully operational.

Dr. Chris Chen, CEO of Wuxi Biologics, noted, “The new commercial capacity in Worcester, Massachusetts represents a key part of our global biomanufacturing network, reflecting our commitment to continuously strengthen our capabilities in line with anticipated market and client needs. We look forward to providing more efficient and cost-effective manufacturing processes and enabling our clients to bring new biologics to patients.”

Last year, Wuxi Biologics launched its first Boston Research Service Center, marking its fourth site in the U.S. after its clinical manufacturing facility in New Jersey and process development and characterization laboratories in Pennsylvania. Upon the Worcester facility construction work going at full speed and operational by 2025, the company is well set to provide full-spectrum integrated services in the U.S., encompassing biologics discovery and development as well as clinical and commercial manufacturing.

(ID:49880892)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent